Summary: In an open-label trial in type 2 diabetes with fatty liver disease, a high-fibre cereal supplement providing 24 g/day of fibre improved the FIB-4 fibrosis index and lowered HbA1c more than control, with the 24 g dose outperforming 12 g, and without a change in BMI.
PICO Summary
| Element | Detail |
|---|---|
| Population | Patients with type 2 diabetes and metabolic-dysfunction-associated steatotic liver disease (MASLD); open-label randomised trial (1:1:1), 12 weeks, Shanghai. |
| Intervention | Dietary-fibre cereal supplement: 24 g/day (two packets) or 12 g/day (one packet), on top of diabetes education. |
| Comparison | Control with traditional diabetes education and typical low fibre intake. |
| Outcome | HbA1c fell more with fibre, significant for 24 g versus control (-1.6% vs -0.6%; p<0.001). The 24 g group had lower fasting glucose at weeks 8 and 12. FIB-4 fell significantly in both fibre groups, most in the 24 g group. BMI did not change significantly, possibly from extra calories in the supplement. |
High-fibre cereal in T2DM with MASLD
Open-label RCT · T2DM + MASLD · 12 weeks
A cereal delivering 24 g/day of dietary fibre lowered HbA1c by 1.6% versus 0.6% with education alone and improved the FIB-4 fibrosis index, without weight change. Promising adjunct advice, but open-label with surrogate endpoints.
Expert Commentary
This is an encouraging dose-ranging trial in a high-prevalence, high-stakes combination, since fatty liver affects the majority of patients with type 2 diabetes and fibrosis is what ultimately drives liver-related harm. The design’s strength is the dose comparison: a clearer effect at 24 g than at 12 g of fibre lends internal credibility, and the biology is well-grounded, soluble fibre slows glucose absorption and is fermented to short-chain fatty acids that improve insulin sensitivity and dampen hepatic inflammation via the gut-liver axis. That FIB-4 improved without weight change is the most interesting claim, hinting at a weight-independent hepatic benefit, though FIB-4 is a non-invasive surrogate rather than biopsy-proven fibrosis regression, so I would not overstate it. The limitations are real: a single-centre, open-label design without blinding, a relatively short twelve weeks, surrogate liver endpoints, and added calories that complicate the weight interpretation. Can I use this with my patients? Yes, comfortably as dietary advice. It reinforces actively pushing fibre intake toward recommended levels in diabetic patients with fatty liver, using accessible high-fibre cereals, while framing it as a plausible adjunct to weight management and proven therapies rather than a proven cure for fibrosis.
References
Chen XS, Liu HZ, Huang F, et al. Impact of a high dietary fiber cereal meal intervention on the progression of liver fibrosis in T2DM with MASLD. Front Endocrinol (Lausanne). 2025;16:1623136. doi:10.3389/fendo.2025.1623136